Kempower Establishes a New Facility for EV Chargers to Meet Global e-Mobility Demand, Scales up Production by the End of 2022
1.7.2021 13:56:00 EEST | Business Wire | Press release
Kemppi Group Oy, the owner of Kempower Oy, acquires a business property managed by S-Bank Properties, including 10 300 m2 of factory space. The new facility will enable Kempower to scale up production by approximately 500% compared to its current capacity. Kempower will gradually ramp up production in 2021-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005423/en/
Kempower establishes a new facility for EV chargers. Photo by Kempower. (Photo: Business Wire)
Kempower, a leading e-mobility charging technology provider in the Nordics, responds to the rapidly growing e-mobility market demand by scaling up production gradually by the end of 2022. Kemppi Group Oy, the owner of Kempower Oy, acquires a business property including 10 300 m2 of factory space. The business property includes extensive unused building right to further expand production in the future. The seller in the transaction is the insurance group Fennia, for which S-Bank's subsidiary S-Bank Properties Ltd provides real estate portfolio management and administration services.
The factory, originally built in 2007 and expanded in 2020, is located in Rälssinkatu 1, Lahti, Finland, with excellent transport connections. Kemppi Group will lease the factory to Kempower. The new facility will enable Kempower to expand its production by approximately 500% compared to the current capacity. Kempower’s production will be scaled up for the second time in a short time: at the beginning of 2021, Kempower increased its production by five times from the 2020 level.
“As Kempower’s owners, we are very committed to the company. Kempower has a lot of growth potential and the international EV charging market has reacted positively to Kempower’s DC charging offering. With this investment, we want to ensure Kempower’s ability to respond to the market demand”, states Antti Kemppi, Chairman of the Board of Kemppi Group & Kempower.
”We are particularly pleased to be able to continue the life of this valuable business property and to provide new jobs in the Lahti region”, Antti Kemppi adds.
“It’s great that this well-kept property found a new home. I believe that the site's modern production facilities offer a great platform to develop business in the future” says Harri Oravainen, Real Estate Investment Director, S-Bank Properties.
“Our aim is to be the preferred partner in the world in developing emission-free business. Our ultimate goal is to create an EV charging infrastructure so extensive and reliable, that the electric vehicles can and will be the new reality. With the new facility, we are able to support our customers in developing emission-free business even faster than before”, states Tomi Ristimäki, CEO, Kempower.
“In the new facility, Kempower will have all the essential functions in one location, including production, R&D, laboratory, testing and offices. The new facility will allow us to be efficient and agile as all the teams will be working seamlessly under one roof”, says Tomi Ristimäki, CEO, Kempower.
The preparations for Kempower’s new facility will start immediately. To ensure customer deliveries, Kempower will gradually ramp up production in 2021-2022. All company functions will be moved to the new location by the end of 2022.
Catella Asset Management acted as Kemppi Groups’ buyside advisor and HPP Attorneys as legal advisors on the transaction.
Kempower designs and manufactures DC fast charging solutions for electric vehicles and machines operating in the most demanding conditions. We are a largescale charging system supplier, aiming for a smoothly running electric mobility infrastructure. With 70 years of experience in perfecting power sources, we set the bar high in engineering and user-experience design. Over 90% of our materials & components are sourced from Finland. Kempower DC charging solutions are designed and manufactured in Lahti, Finland, and available globally. www.kempower.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005423/en/
Contact information
For more information, please contact:
Tomi Ristimäki
CEO
Kempower Oy
tomi.ristimaki@kempower.com
+358 44 289 9815
Kempower media contacts
Paula Savonen
Marketing & Communications manager
paula.savonen@kempower.com
+358 400 343 851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom